#USA #San Francisco #Stämm #Bioreactor #Antibodies

A New Era in Bioprocessing with Stämm's Continuous Bioreactor

In an exciting development for the biopharmaceutical sector, Stämm has introduced a revolutionary continuous bioreactor designed to enhance the productivity of monoclonal antibodies. Recent pilot projects conducted in countries including Germany, Switzerland, and Argentina have revealed remarkable outcomes from this innovative technology.

Transformative Productivity Gains

The bioreactor, known for its continuous laminar flow operation without bubbles, has achieved a minimum of 15 times greater volumetric productivity compared to traditional batch systems, with projections suggesting up to 50 times increased productivity in 2025. These efficiency gains also encompass a notable fourfold increase in cell density and specific productivity, which are critical metrics in bioprocessing.

This desktop plug-and-play unit not only reduces operational costs but also minimizes downtime while ensuring high product quality. Its versatility allows it to manage both adherent and suspension cultures effectively. As healthcare systems face increasing demands for advanced therapies, such as biologics targeting chronic and complex diseases, Stämm plays a pivotal role in enabling rapid commercialization of biopharmaceuticals and biosimilars.

Streamlining Biofabrication Processes

The closed-system design of Stämm's bioreactor utilizes single-use 3D printed cartridges that streamline scalability and cost efficiency. Following successful pilot implementations completed in under three months, this technology is poised for global deployment in underserved markets.

The consistent and stress-free environment provided by the continuous bioreactor ensures optimal conditions, characterized by high gas exchange rates. This contributes significantly to the overall yield and quality of biosimilar production, addressing an urgent need in oncology and immunology.

A Sustainable Future for Biopharmaceuticals

As the biopharmaceutical industry approaches a critical juncture with impending patent expirations, solutions like Stämm's bioreactor are invaluable. The company positions itself as a key partner in facilitating accessible and scalable biofabrication solutions. Collaborative efforts with early adopters are already underway, aiming to redefine the standards of biofabrication and advance next-generation medicines.

Founded in 2016, Stämm remains committed to innovation in the biomanufacturing sector by developing fully automated bioprocessors. Its bubble-free continuous manufacturing platform not only improves yield but also reduces costs, space requirements, and energy consumption.

The overarching goal of Stämm is to decentralize bioprocessing, allowing partners to focus on disruptive discoveries that can positively impact health outcomes worldwide. For further information, visit Stämm's official website.

Conclusion

Stämm's continuous bioreactor heralds a new era in the biopharmaceutical industry by significantly enhancing the efficiency of antibody production. This innovative approach not only addresses the growing demand for high-quality biologics but also sets a new benchmark for sustainability and scalability in biofabrication. As the industry adapts to evolving challenges, Stämm stands ready to lead the charge with its state-of-the-art technology.